<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947687</url>
  </required_header>
  <id_info>
    <org_study_id>601-0001P-00</org_study_id>
    <nct_id>NCT00947687</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmatrix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Retroscreen Virology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pulmatrix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to demonstrate the effectiveness, safety and tolerability of
      multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults
      experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.</measure>
    <time_frame>Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score</measure>
    <time_frame>Day 6 of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative viral shedding from nasal viral inoculation until day 6</measure>
    <time_frame>Day 0 to day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bioaerosol output with treatment and after viral inoculation</measure>
    <time_frame>Day -2 to day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PUR003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR003</intervention_name>
    <description>Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days</description>
    <arm_group_label>PUR003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 18 to 45 years.

          -  In general good health determined by a screening evaluation ≤120 days prior to
             double-blind IMP administration and on the day of admittance to quarantine.

          -  Seronegative (NDA) for challenge virus.

          -  Have not been vaccinated for influenza virus since 2006 (as determined in the medical
             history) or had a known influenza infection in the current season, defined as in the
             last 12 months.

        Exclusion Criteria:

          -  Presence or evidence of significant acute or chronic, uncontrolled medical or
             psychiatric illness.

          -  Abnormal pulmonary function as evidenced by clinically significant abnormality in
             spirometry.

          -  Health care workers (including doctors, nurses, medical students and allied healthcare
             professionals) anticipated to have patient contact within two weeks of discharge from
             quarantine.

          -  Intending to travel (to countries for which vaccinations are recommended or where high
             risk of infections exists).

          -  Presence of household member or close contact (until 14 days after discharge from
             quarantine) who is: less than 3 years of age; has any known immunodeficiency; is
             receiving immunosuppressant medications; is undergoing or soon to undergo cancer
             chemotherapy within 28 days of challenge.

          -  Subjects with diagnosed emphysema or chronic obstructive pulmonary disease (COPD);
             elderly residing in a nursing home, affected by severe lung disease or medical
             condition; or a transplant (bone marrow or solid organ) organ recipient

          -  Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway
             disease, or any chronic lung condition of any aetiology.

          -  Regular daily smokers during the 6 months prior to study entry or those who have a
             significant history of any tobacco use at any time (≥ total 10 pack year history = one
             pack a day for 10 years).

          -  Presence of any febrile illness or symptoms of upper or lower tract respiratory
             infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated
             for enrolment after resolution of the illness).

          -  Receipt of any investigational drug within 3 months, or prior participation in a
             clinical trial of any influenza vaccine or medication within 1 year of participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Hanrahan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pulmatrix Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guys Drug Research Unit (GDRU), Quintiles Ltd</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>healthy subject</keyword>
  <keyword>virus inoculation</keyword>
  <keyword>symptom scores</keyword>
  <keyword>viral shedding</keyword>
  <keyword>bioaerosol output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

